Direct lipolysis & adrenergic drive
One of 6 mechanistic pathways to 🔥 Lose fat · 15 options
Skip the brain and the mitochondrion and act on the fat cell itself. β-adrenergic receptors on adipocytes trigger hormone-sensitive lipase; GH fragments do something similar without the glucose consequences of full GH. Fast-acting, and the same receptors sit on your heart, which is the entire safety story of this pathway.
This pathway leans on beta-adrenergic signaling, so it stacks on top of whatever your sympathetic tone already is. High cortisol plus a stimulant is how people get palpitations, insomnia and a worse result than they started with. Check before you add adrenergic drive, not after.
Cortisol (AM)TSH (Thyroid-Stimulating Hormone)Free T3 (Triiodothyronine)hs-CRP (High-Sensitivity C-Reactive Protein)🌡️ Adrenal & Cortisol Axis covers these in one panel →
What engages this pathway
Ordered by how directly each one acts on the mechanism above — never by how much trial evidence exists. Each links to its full breakdown with dosing, half-life and vendor.
🧬 Forskolin
The reagent every cell biologist uses to raise cAMP by activating adenylyl cyclase DIRECTLY, bypassing the receptor — which is why it appears in thousands of papers as a positive control. The gap between that and a capsule is exposure: the arithmetic on an oral dose puts the plasma ceiling far below the concentration used at the bench, and no human oral pharmacokinetic study of it exists.
💉 AOD-9604
The C-terminal fragment of GH engineered to keep the lipolytic action and lose the IGF-1 and glucose effects. Human trials for obesity failed their weight endpoints — but the mechanism is real and the extrapolation people make is toward localized use and stacking, which was never what was tested.
💉 Clenbuterol
β2-agonist. Raises lipolysis and metabolic rate and is genuinely effective; it also raises heart rate, causes cardiac hypertrophy with chronic use, and depletes taurine. Effective is not the same as advisable.
💉 Albuterol
The same β2 receptor Clenbuterol hits, with a much shorter half-life and an approved oral dose behind it. Cyclic AMP rises in the adipocyte so lipolysis rises, and animal work plus small human studies also show an anti-catabolic effect on skeletal muscle. Receptors downregulate under continuous stimulation, which is why it is cycled — and the tremor, tachycardia and potassium shift are the same receptor doing its other job.
💉 Mirabegron
β3-agonist approved for overactive bladder. β3 receptors sit on brown adipose tissue — human PET imaging shows it activates BAT and raises resting energy expenditure. This is one of the more elegant extrapolations available: an on-label drug with an off-label mechanism that actually images.
💉 Lipotropic Blend
Carnitine plus MIC plus B12 plus a small amount of albuterol. The albuterol is doing the lipolytic work; the rest is substrate support. Mind stimulant and cardiac sensitivity.
💉 Lipo-C
The lipotropic injection without the beta-agonist — methionine, inositol, choline and carnitine. Supports hepatic fat export rather than driving lipolysis.
💉 L-Carnitine
Injectable carnitine bypasses the poor oral absorption problem. Still only useful if fatty-acid transport is actually your bottleneck.
💉 Nad+/Carnitine Amino Blend
Combines the NAD+ and carnitine arguments in one vial — substrate transport plus cofactor availability.
💉 DADA
A research adrenergic-pathway compound with essentially no human characterization. Listed for completeness; the honest position is that nobody knows.
🧬 Yohimbine
α2-antagonist. α2 receptors act as a brake on lipolysis and are densest in stubborn fat — lower body in women, lower abdomen in men. Blocking them raises regional blood flow and fat mobilization, and the effect is strongest fasted. Anxiety and blood-pressure response are dose-limiting.
🧬 Caffeine
Phosphodiesterase inhibition and adenosine antagonism raise cAMP, which raises lipolysis, plus a real thermogenic effect. Tolerance develops to the thermogenesis faster than to the stimulation.
🧬 Paraxanthine
Caffeine's primary metabolite and the one doing much of the work. Cleaner subjective profile with less anxiogenic pressure; the fat-oxidation claim is extrapolated from caffeine's.
🧬 Green Tea (EGCG)
EGCG inhibits COMT, slowing noradrenaline breakdown so the adrenergic signal at the adipocyte lasts longer. Meta-analyses show a small but real effect, and it's synergistic with caffeine for exactly this reason.
🧬 Theacrine
Structurally close to caffeine with slower tolerance development. The lipolysis argument is by analogy rather than by trial.
What actually decides this outcome, in order of size
This page acts on a receptor family that is not confined to fat cells, and that single fact organizes everything below it. Ranked by how much of the outcome each one owns:
- Which adrenergic receptor subtype is being engaged, because the same signal in a different tissue is the side-effect profile. Beta-2 agonism raises adipocyte cyclic AMP and hormone-sensitive lipase activity, and it also produces tremor, tachycardia and a potassium shift, because the receptor sits in muscle, heart and vasculature too. Beta-3 is the interesting exception: it is concentrated in adipose and bladder, which is why an approved beta-3 agonist has been discussed as a potential anti-obesity drug on the basis of tissue distribution rather than potency Dąbrowska 2023.
- Whether mobilization is the same as oxidation, because it is not. Lipolysis releases fatty acids into circulation. If they are not oxidized they are re-esterified and stored again, which is why an agent that raises circulating free fatty acids has demonstrated mobilization and nothing else. The energy demand that decides the fate of those fatty acids is not on this shelf.
- What has actually been imaged in humans, because two entries here have been. A beta-3 agonist has human data on brown adipose and glucose handling Waki 2021, with a negative combination result against a thiazolidinedione Finlin 2021, and the licensed indication and full safety information sit in its prescribing information Myrbetriq label 2024. Separately, beta-2 stimulation with salbutamol activated human brown adipose tissue Straat 2023. That is a small, real, measured literature under a large, loud category.
- Cardiac tolerance, which is the entire safety story of the prescription half. Clenbuterol misuse in bodybuilding and athletics has been characterized including the unsupervised use pattern Kataveni 2025. Chronic beta-2 stimulation produces cardiac hypertrophy and receptor downregulation, and the downregulation is why the compound is cycled rather than titrated.
- Whether the growth hormone fragment does what its marketing claims, which has been tested. Metabolic studies of the synthetic lipolytic domain of human growth hormone exist Ng 2000, seized preparations of peptide drugs have been analyzed for identity Vanhee 2014, and the landscape of performance peptides modulating this axis has been reviewed Dominikowski 2026. The obesity trials failed their weight endpoints. The mechanism is real and the extrapolation people make toward localized use was never the thing that was tested, which is labeled here as an extrapolation.
- The supplement end, last, and its effect size is bounded by measurement noise. Green tea catechins change resting metabolic rate and respiratory quotient measurably and modestly, and the systematic review is where to see the size Rondanelli 2021. Caffeine tolerance develops to the thermogenic effect faster than to the stimulation, and its half-life is long enough that an afternoon dose reaches bedtime Drake 2013. Theacrine has human pharmacokinetic work including an interaction assessment with caffeine He 2017 and a trial on vigilance and hemodynamics Cintineo 2022.
The order to run these in, and what has to be true first
Establish cardiac tolerance, use the tolerable levers, and treat the prescription half as a prescription. The order is set by the receptor distribution rather than by potency.
- Baseline observations before anything with a beta agonist in it. Resting heart rate and blood pressure measured seated and rested on several days, plus Comprehensive Metabolic Panel (CMP) for potassium and renal function, Complete Blood Count (CBC) with Differential, HbA1c (Hemoglobin A1c) and Free T3 (Triiodothyronine). Palpitations, known arrhythmia, uncontrolled blood pressure or cardiac symptoms move this page out of reach and into a clinic.
- Resistance training and adequate protein alongside anything here, from the beginning. This is on the page because the compartment question belongs to Lose fat and Lean-mass protection while cutting, and because an adrenergic agent does nothing to defend lean tissue.
- Caffeine first, because it is the cheapest lever with a real mechanism and a known tolerance curve. Phosphodiesterase inhibition and adenosine antagonism raise cyclic AMP. Its half-life means a dose six hours before bed still measurably disrupts sleep Drake 2013, and sleep is upstream of everything on this goal.
- Green Tea (EGCG) next and for the right reason. Catechins slow catecholamine breakdown, which extends the adrenergic signal at the adipocyte rather than creating one, and the measured effect on resting metabolic rate and respiratory quotient is modest Rondanelli 2021. That is why it is described as synergistic with caffeine rather than as an alternative to it.
- Yohimbine next if regional mobilization is the specific target, and with the blood pressure question settled first. Alpha-2 receptors act as a brake on lipolysis and are dense in the regions people complain about; blocking them raises regional blood flow and mobilization. Anxiety and blood-pressure response are dose-limiting and are the same receptor doing its other job.
- Theacrine and Paraxanthine are the caffeine-adjacent end and are argued by analogy. Theacrine has human pharmacokinetics and a caffeine interaction assessment He 2017 and a trial on vigilance and hemodynamics Cintineo 2022; the fat-oxidation claim for both is extrapolated from caffeine rather than measured, and is labeled as an extrapolation.
- L-Carnitine and Lipo-C are transport and hepatic export arguments rather than lipolytic ones. Increasing skeletal muscle carnitine content in older people increased whole-body fat oxidation Chee 2021, and carnitine supplementation improved insulin sensitivity and skeletal muscle acetylcarnitine formation Op den Kamp-Bruls 2025. Raising muscle carnitine is difficult and slow, which is the practical objection to the injectable shortcut.
- Mirabegron, Albuterol and Clenbuterol are prescription decisions in descending order of tissue selectivity. The beta-3 agonist has an approved indication, prescribing information Myrbetriq label 2024 and human metabolic data Waki 2021 Finlin 2021; albuterol has an approved oral dose and a short half-life; clenbuterol has the cardiac hypertrophy and misuse literature Kataveni 2025. DADA has essentially no human characterization and the honest position is that nobody knows.
What gets bought for this that cannot move it
The category that fails structurally is the fat burner judged on how it feels. Tremor, warmth and a raised heart rate are the receptor being engaged in muscle, skin and myocardium. They correlate with dose and they do not correlate with adipose outcome, which means the sensation everybody uses as feedback is a measurement of the side effects. That is why the read-out below is a blood potassium and a resting heart rate rather than a subjective one.
The surrogate on this page is mobilization, and mobilization is not disposal. An agent that raises circulating free fatty acids has shown that it opens the door. If those fatty acids are not oxidized they are re-esterified, and the published human work on this class measures resting metabolic rate, respiratory quotient and brown adipose activation Rondanelli 2021 Straat 2023 Waki 2021 rather than a body composition endpoint. Reading a mobilization result as a fat-loss result is the single commonest error in the whole category.
The growth hormone fragment is the specific case worth knowing. Its lipolytic domain has metabolic studies behind it Ng 2000 and its obesity trials did not meet their weight endpoints. Seized preparations in this family have been analyzed for identity Vanhee 2014, which makes the contents of an unlicensed vial a live question, and the wider peptide landscape around this axis has been reviewed Dominikowski 2026. A page that lists the mechanism and omits the failed endpoint is not describing the compound.
If the goal underneath is different, so is the page. If resting metabolic rate has fallen, that is Thyroid & thermogenic substrate and it is a substrate question rather than a stimulant one. If insulin is keeping hormone-sensitive lipase switched off, Substrate partitioning & insulin control. If the interest is cellular energy expenditure, Mitochondrial & metabolic reprogramming is the page that argues it. If eating is a source of distress rather than a quantity problem, this pharmacology is the wrong instrument and the right step is a clinician who works with eating. And chest pain, palpitations or syncope on any agent here is an emergency rather than a dose adjustment.
How you would know it was working, on a real read-out and a real timescale
This page makes two predictions. Serum potassium falls on beta-2 agonism, because the receptor drives potassium into cells, and that is a checkable pharmacodynamic signature rather than a rare adverse event; and resting heart rate rises on every effective agent here, which makes it the cheapest exposure marker on the page and the one that should govern the dose.
- Resting heart rate and blood pressure daily, seated, rested, same time. Two weeks of baseline before starting anything. This is the dose-limiting read-out for the entire adrenergic half of the page Kataveni 2025.
- Comprehensive Metabolic Panel (CMP) at baseline and 2 weeks on any beta-2 agonist, watching potassium. Two weeks because the shift is a direct receptor effect rather than a cumulative one, so it is present early or not at all. Magnesium, RBC beside it, because magnesium and potassium handling travel together and both contribute to arrhythmia risk.
- Complete Blood Count (CBC) with Differential and HbA1c (Hemoglobin A1c) at baseline and 12 weeks. Beta agonists raise glucose acutely through hepatic glycogenolysis, and knowing the starting value is what turns a later reading into information.
- Free T3 (Triiodothyronine) at baseline and 12 weeks if this is being run during a sustained deficit. It falls as an adaptation, which is the denominator problem that Thyroid & thermogenic substrate exists for, and a stimulant does not fix it.
- Waist circumference at a marked landmark and one strength measure, weekly. Mark the site. Falling strength alongside falling mass says the compartment that moved is not the one you wanted, which is the argument Lose fat makes at length.
What will fool you. Stimulants raise heart rate, temperature and subjective energy within an hour, and none of that predicts adipose outcome. Caffeine tolerance develops to the thermogenic effect faster than to the stimulation, so the felt effect outlives the metabolic one Rondanelli 2021. A late dose disrupts sleep measurably even when it does not feel like it Drake 2013, and sleep loss works against everything on this goal. Yohimbine's anxiety and pressor response is the same receptor blockade as the intended effect, so it cannot be dosed away. Brown adipose activation is a real imaged endpoint and is not a body composition endpoint Straat 2023 Waki 2021. And an unlicensed vial of a peptide in this family may not contain what the label says Vanhee 2014.
Sources read for these sections
- Dąbrowska AM, Dudka J. Mirabegron, a Selective beta3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug. Journal of Clinical Medicine 2023 · PMID 37959362
- Waki H, et al. Body-weight-independent glucose-lowering effect of the beta3-adrenergic receptor agonist mirabegron in humans. Journal of Diabetes Investigation 2021 · PMID 33460524
- Finlin BS, et al. Pioglitazone does not synergize with mirabegron to increase beige fat or further improve glucose metabolism. JCI Insight 2021 · PMID 33571166
- U.S. Food and Drug Administration. MYRBETRIQ (mirabegron) extended-release tablets — full prescribing information. DailyMed, U.S. National Library of Medicine, label revised 2024
- Straat ME, et al. Stimulation of the beta-2-adrenergic receptor with salbutamol activates human brown adipose tissue. Cell Reports Medicine 2023 · PMID 36812890
- Kataveni S, et al. Clenbuterol Abuse in Bodybuilding and Athletics: Unsupervised Use, Psychological Motivations, and Health Consequences. Cureus 2025 · PMID 40575216
- Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.. Horm Res 2000 · PMID 11146367
- Vanhee C, Moens G, Deconinck E, De Beer JO. Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604.. Drug Test Anal 2014 · PMID 24976118
- Dominikowski A, Rekos Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchala M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.. Front Endocrinol (Lausanne) 2026 · PMID 42395176
- Rondanelli M. Effect of Acute and Chronic Dietary Supplementation with Green Tea Catechins on Resting Metabolic Rate, Energy Expenditure and Respiratory Quotient: A Systematic Review. Nutrients 2021 · PMID 33671139
- Drake C. Caffeine effects on sleep taken 0, 3, or 6 hours before going to bed. Journal of Clinical Sleep Medicine 2013;9(11):1195-1200 · PMID 24235903
- He H, Ma D, et al. Assessment of the Drug-Drug Interaction Potential Between Theacrine and Caffeine in Humans. Journal of Caffeine Research 2017 · PMID 28875060
- Cintineo HP, Bello ML, et al. Effects of caffeine, methylliberine, and theacrine on vigilance, marksmanship, and hemodynamic responses in tactical personnel: a double-blind, randomized, placebo-controlled trial. Journal of the International Society of Sports Nutrition 2022 · PMID 36016763
- Chee C, et al. Increasing skeletal muscle carnitine content in older individuals increases whole-body fat oxidation during moderate-intensity exercise. Aging Cell 2021 · PMID 33464721
- Op den Kamp-Bruls YMH, et al. Carnitine supplementation improves insulin sensitivity and skeletal muscle acetylcarnitine formation in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2025 · PMID 40019115
The other 5 routes to lose fat
Pick the pathway that matches where you are actually stuck. An appetite drug does nothing for someone who already undereats.
You know the goal. Skool has the plan.
This pathway is one arm of The Lose fat Blueprint. The members' version has where this arm sits in the sequence, what to stack it with, and the markers that tell you to keep going or stop.
Open The Lose fat Blueprint in Skool →$10/mo, cancel anytime.
← Open this pathway in the interactive Vault
Frequently asked questions
Skip the brain and the mitochondrion and act on the fat cell itself. β-adrenergic receptors on adipocytes trigger hormone-sensitive lipase; GH fragments do something similar without the glucose consequences of full GH. Fast-acting, and the same receptors sit on your heart, which is the entire safety story of this pathway.
15 options are mapped to this pathway in the Vault, including Forskolin, AOD-9604, Clenbuterol, Albuterol. They are grouped by the mechanism they act through rather than ranked by how much trial evidence exists — 6 carry clinical validation and 9 are mechanistic predictions.
This pathway leans on beta-adrenergic signaling, so it stacks on top of whatever your sympathetic tone already is. High cortisol plus a stimulant is how people get palpitations, insomnia and a worse result than they started with. Check before you add adrenergic drive, not after. The markers worth checking are Cortisol (AM), TSH (Thyroid-Stimulating Hormone), Free T3 (Triiodothyronine), hs-CRP (High-Sensitivity C-Reactive Protein).
Unproven is not the same as ineffective. Of the 15 options on this pathway, 6 have clinical validation and 9 are graded theoretical — meaning the mechanism is sound but the specific human trial has not been run, which is true of a great deal of what works in this space. Nothing on this page is ordered by evidence tier, because sorting by trial count would bury the compounds you came looking for.
Where this goes next
Everything above is the free case for Direct lipolysis & adrenergic drive. The protocol — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.